PPARG and Hepatic fibrosis: Consistent with the previous results, also is the study of Chen et al. [28] who demonstrated that PPARγ ligand, rosiglitazone, can reduce inflammation and liver fibrosis with Schistosoma infection by reducing TGF-β1 expression.